Vaxcyte, Inc. PCVX Accrued Compensation
Accrued Compensation at other companies
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept pcvx:IncreaseDecreaseInAccruedCompensation.
The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vaxcyte, Inc.'s accrued compensation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vaxcyte, Inc.'s accrued compensation?
- Vaxcyte, Inc. (PCVX) reported accrued compensation of -$15.02M in Q1 2026.
- How has Vaxcyte, Inc.'s accrued compensation changed year-over-year?
- Vaxcyte, Inc.'s accrued compensation decreased by 4.2% year-over-year, from -$14.42M to -$15.02M.
- What is the long-term trend for Vaxcyte, Inc.'s accrued compensation?
- Over 2 years (2021 to 2024), Vaxcyte, Inc.'s accrued compensation has grown at a 73.3% compound annual growth rate (CAGR), from $3.17M to $9.52M.
- What does accrued compensation mean?
- This reflects the net change in liabilities related to employee compensation, such as bonuses, salaries, and benefits that have been earned but not yet paid. An increase indicates a deferral of cash outflows, while a decrease represents the settlement of these obligations. It serves as a proxy for short-term liquidity management regarding human capital costs.